medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2013, Número 4

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2013; 60 (4)


Estabilidad del antígeno prostático específico total bajo diferentes condiciones de almacenamiento en muestras cubanas

García FI, Pereda MCM, Salles FL, Picans RF, Pedraye SY, Guerra M

Idioma: Español
Referencias bibliográficas: 24
Paginas: 239-243
Archivo PDF: 258.80 Kb.


RESUMEN

La diferencia en la estabilidad de la molécula del antígeno prostático específico total (PSAT) puede influenciar la utilidad clínica de este ensayo. Objetivo: Evaluar la estabilidad en el tiempo del antígeno prostático específico total, a diferentes temperaturas de almacenamiento. Métodos: Se tomaron aleatoriamente siete alícuotas de suero de 20 individuos. Se cuantificó el PSAT inicial y se guardó el resto por duplicado -10 oC, -20 oC y -70 oC. Se volvió a cuantificar el PSAT pasados 7 y 30 días. Resultados: A la semana, los valores disminuyeron 21.88%, 11.14% y 7.61% a -10 oC, -20 oC y -70 oC, respectivamente, sin diferencias significativas (p ≥ 0.05). Al mes, decayeron 32.67%, 31.45% y 21.47% a -10 oC, -20 oC y -70 oC, respectivamente, sin diferencias significativas (p ≥ 0.05). La mayor variación se observó en los valores de PSAT entre 4-10 ng/mL almacenados a -10 oC. Conclusiones: Los resultados sugieren que las muestras se deben almacenar a -20 oC o menos por una semana. Cuando el tiempo de almacenaje se prolonga por un mes o más, éste se debe realizar a -70 oC; sobre todo porque los valores de PSAT entre 4 y 10 ng/mL son más afectados con la temperatura.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008; 8: 268-278.

  2. Niemela P, Lovgren J, Karp M, Lilja H, Pettersson K. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate specific antigen after an activation step. Clin Chem. 2002; 48: 1257-1264.

  3. Pironen T, Pettersson K, Suopaa M, Stenman UH et al. In vitro stability of free prostate specific antigen (PSA) and prostate specific antigen complexed to α-1 antichymotrypsin in blood samples. Urology. 1996; 48: 81-87.

  4. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006; 67: 762-768.

  5. Price CP, Allard J, Davies G,et al. Pre- and post- analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem. 2001; 38: 188-216.

  6. Bruun L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 2003;18:598–603.

  7. Sutcliffe S, Platz EA. Inflammation in the etiology of prostate cancer: An epidemiologic perspective. Urol Oncol. 2007; 25: 242-249.

  8. Reiter RE, deKernion JB. Epidemilogy, etiology, and prevention of prostate cancer. In: Walsh PC et al (eds). Campell’s Urology. Philadelphia: Saunders; 2002. p. 3003–3024.

  9. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009; 181: 2064–2070.

  10. Jung K, Lein M, Brux B et al. Different stability of free and complexed protate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med. 2000; 38: 1271-1275.

  11. Bruun L, Becker Ch, Hugosson J, Lilja H, Christensson A. Assessment of Intra-Individual Variationin Prostate-Specific Antigen Levels in a Biennial Randomized Prostate Cancer Screening Program in Sweden. Prostate. 2005; 65 (3): 216–221.

  12. Wolf A, Wender RC, Etzioni R, Thompson I, D’AmicoA, Volk Aj et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer. Update 2010. CA Cancer J Clin. 2010; 60: 70–98.

  13. Cartledge JJ, Thompson D, Erril H et al. The stability of free and bound prostate-specific antigen. BJU Int. 1999; 84: 810-814.

  14. Paus E, Nilsson O, Bormer OP et al. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and bening hyperplasia. J Urol. 1998; 159: 1599-1605.

  15. Arcangeli CG, Smith DS, Ratliff TL et al. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol. 1997; 158: 2182-2187.

  16. Jung K, V. Klinggräff P, Brux B, Sinha P, Schnorr D, Loening SA. Preanalytical determinants of total and free prostate-specific antigen and their rario: blood collection and storage conditions. Clin Chem. 1998; 44: 685-688.

  17. Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. Urology. 1998; 39: 2098-2103.

  18. Kumari G.R. and Malati T. Stability of Total and Free Prostate Specific Antigen in Serum Samples at Different Storage Conditions. Indian J Clin Biochem. 2004; 19 (2): 10-13.

  19. Blijenberg BG, Roobol M, Shroder FH et al. Analitycal issues on prostate specific antigen in relation to prostate cancer screening. Clin Biochem. 1998; 31: 633-639.

  20. Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA. Five year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70 degrees C or less. Int J Biol Markers. 2007; 22 (3): 206-13.

  21. Sokoll L, Bruzek DJ, Dua R et al. Short term stability of molecular forms of prostate specific antigen and effect on percent complexed prostate specific antigen and percent of free prostate specific antigen. Urology. 2002; 60: 24-30.

  22. Leinonen J, Stenmam UH. Reduced stability of prostate-specific antigen after long-temr storage or serum at –20 degrees C. Tumour Biol. 2000; 21: 46-53.

  23. Nixon RG, Wener MH, Smith KM, Parson RE, Blase AB, Brawer MK. Day to day changes in free and total PSA: Significance of biological variation. Prostate Cancer Prostatic Dis. 1997; 1: 90-96.

  24. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem. 2002; 35: 471-475.




2020     |     www.medigraphic.com